NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Is Up 13.0% After FDA Approves Lifyorli Combo in Resistant Ovarian Cancer
In March 2026, Corcept Therapeutics received FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after one to three prior regimens including bevacizumab.
This approval, grounded in the ROSELLA trial’s survival benefit and establishing Lifyorli as the first FDA-approved selective glucocorticoid receptor antagonist, materially expands Corcept’s oncology footprint and validates its...